RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Alirocumab Has Greater Reduction of LDL-C Than Ezetimibe in Patients with Statin Intolerance
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 52
SP 16
OP 17
DO 10.1177/155989771452008
UL http://mdc.sagepub.com/content/14/52/16.abstract
AB In clinical practice, up to 25% of patients are statin intolerant as a result of symptoms and abnormalities in biomarkers. This article discusses results from the Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular Risk, Who Are Intolerant to Statins [Odyssey Alternative; NCT01709513]. These trials compared statin intolerant patients who were treated with alirocumab versus ezetimibe.